Growth Factor News and Research

RSS

Glioblastoma's molecular flexibility helps resist nearly all treatment efforts

Glioblastoma, the most common and lethal form of brain cancer and the disease that killed Massachusetts Senator Ted Kennedy, resists nearly all treatment efforts, even when attacked simultaneously on several fronts. One explanation can be found in the tumor cells' unexpected flexibility, discovered researchers at the Salk Institute for Biological Studies.

25 Jan 2011

ArQule's ARQ 197 Phase 1 clinical trial results in colorectal cancer presented at ASCO 2011

ArQule, Inc. today announced the presentation of Phase 1 results of a clinical trial among patients with metastatic colorectal cancer (CRC) treated with ARQ 197, a selective small molecule inhibitor of the c-MET receptor tyrosine kinase, in combination with irinotecan and cetuximab. ARQ 197 is under development by Daiichi Sankyo Co., Ltd. and ArQule.

24 Jan 2011

FibroGen announces FG-3019 interim results from phase 1/2 trial against pancreatic cancer

FibroGen, today announced interim results of a phase 1/2 trial of FG-3019, a therapeutic antibody against connective tissue growth factor, in combination with gemcitabine and erlotinib in individuals with unresectable pancreatic cancer.

23 Jan 2011

Novel FAK inhibitors targeting binding site of VEGFR-3 reduce growth of pancreatic cancer cells

CureFAKtor Pharmaceuticals, LLC, a privately-held biopharmaceutical company focused on the research and development of Focal Adhesion Kinase (FAK) inhibitors for cancer, today presented research results at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco demonstrating that novel FAK inhibitors targeting the binding site of vascular endothelial growth factor receptor 3 (VEGFR-3) reduced the growth of pancreatic cancer cells in vitro and in vivo.

21 Jan 2011

MedImmune announces MEDI-573 preclinical results against many solid tumors

MedImmune's Oncology group announced today preclinical results showing that MEDI-573, a targeted monoclonal antibody, broadly suppresses pathways that have been shown to play a critical role in the development and progression of many solid tumors.

21 Jan 2011

New study reveals illicit HGH use among young American male weightlifters

A new study published in The American Journal on Addictions reveals that illicit use of HGH has become common among young American male weightlifters.

21 Jan 2011

Biomarin commences BMN 701 Phase 1/2 trial for treatment of Pompe disease

BioMarin Pharmaceutical Inc. announced today that it has initiated a Phase 1/2 trial for BMN 701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase in development for the treatment of Pompe disease.

20 Jan 2011

Scientists produce tiny molecular 'binder' that may help develop more efficient drugs

Developing new drugs is a highly costly and time-consuming process. Of 20 candidates, 19 are normally rejected because they don't work or have unwanted side effects. Now a research team led by Professor Lars Baltzer at Uppsala University has produced a tiny molecular "binder" that has the potential to change this landscape radically.

19 Jan 2011

Postmenopausal women receiving estrogen plus progestin at increased risk of breast cancer

Researchers have identified how the hormones progesterone and estrogen interact to increase cell growth in normal mammary cells and mammary cancers, a novel finding that may explain why postmenopausal women receiving hormone replacement therapy with estrogen plus progestin are at increased risk of breast cancer.

19 Jan 2011

Platelet-rich plasma shows a promising biologic treatment for myocardial infarction: Study

Researchers at the Stanford University School of Medicine, in collaboration with BioParadox, Inc., have published data supporting the use of platelet-rich plasma as a promising biologic treatment for myocardial infarction.

18 Jan 2011

pH Advantage adds Pyranase to facial skin care line

pH Advantage LLC recently added a new breakthrough product to its highly effective facial skin care line. Pyranase is clinically proven to reverse the signs of aging, reduce fine lines and wrinkles and improve the overall texture and appearance of the skin. Pyranase brings the proven effectiveness of a class of plant growth factor (cytokinin) in an enhanced and proprietary molecular formula.

14 Jan 2011

12-HETE enzyme inhibition can prevent ischemic retinopathy: Study

The inhibition or removal of an enzyme may prevent or treat ischemic retinopathy by stalling growth of unwanted vessels in the retina, Medical College of Georgia researchers say.

14 Jan 2011

FibroGen initiates FG-3019 open-label phase 2 study in idiopathic pulmonary fibrosis

FibroGen, Inc. today announced initiation of an open-label phase 2 study to evaluate the safety, tolerability, and efficacy of FG-3019, a human monoclonal antibody against connective tissue growth factor (CTGF), in individuals with idiopathic pulmonary fibrosis (IPF), a chronic, progressive, fatal lung disease for which there are no FDA-approved therapies.

13 Jan 2011

Pfizer initiates rolling submission of crizotinib NDA for ALK-positive advanced NSCLC

Pfizer Inc. announced today that it has initiated the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for crizotinib (PF-02341066), an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors are ALK-positive. Pfizer expects to complete the submission in the first half of 2011.

13 Jan 2011

Daiichi Sankyo and ArQule initiate enrollment in ARQ 197 Phase 3 trial in NSCLC

Daiichi Sankyo Company, Limited and ArQule, Inc. today announced that the first patient has been enrolled in the Phase 3 trial of ARQ 197, an investigational selective inhibitor of the c-Met receptor tyrosine kinase, in combination with erlotinib, for patients diagnosed with non-squamous, non-small cell lung cancer (NSCLC) who have received one or two prior systemic anti-cancer therapies.

12 Jan 2011

Basal-like breast cancer is equally aggressive disease in African American women and white women: Study

In 2006, a team from the University of North Carolina at Chapel Hill schools of Public Health and Medicine and UNC Lineberger Comprehensive Cancer Center found that breast cancer in younger African American women is more likely to be the more aggressive basal-like (or triple-negative) subtype - one factor thought to be behind known racial disparity differences in breast cancer patient outcomes.

11 Jan 2011

Nutriceuticals may restore age-related vision loss

While age-related vision loss of catastrophic proportions is predicted in coming decades, rising from 17 million patients today to 55 million by the year 2050, it's possible this catastrophe could be averted and lost vision even restored using molecular medicine.

11 Jan 2011

Scientists discover new anti-cancer mechanism

Scientists attached to VIB and K.U.Leuven have succeeded in decoding a potential new anti-cancer mechanism. The researchers discovered that normalizing abnormal tumor blood vessels through HRG prevents metastasis of tumor cells and enhances chemotherapy efficiency.

10 Jan 2011

HRG protein inhibits tumor growth and metastasis: Study

Most cancer tissues are invaded by inflammatory cells that either stimulate or inhibit the growth of the tumor, depending on what immune cells are involved. Now a Swedish-Belgian research team has shown that a protein that naturally occurs in the body, HRG, inhibits tumor growth and metastasis into secondary organs by activating specific immune cells.

7 Jan 2011

New research: NFKBIA gene loss induces glioblastoma development

New research shows that loss of a gene called NFKBIA promotes the growth of glioblastoma multiforme, the most common and deadly form of brain cancer, and suggests that therapies that stabilize this gene may improve survival for certain glioblastoma patients.

7 Jan 2011

Growth Factor News and Research

Glioblastoma's molecular flexibility helps resist nearly all treatment efforts

ArQule's ARQ 197 Phase 1 clinical trial results in colorectal cancer presented at ASCO 2011

FibroGen announces FG-3019 interim results from phase 1/2 trial against pancreatic cancer

Novel FAK inhibitors targeting binding site of VEGFR-3 reduce growth of pancreatic cancer cells

MedImmune announces MEDI-573 preclinical results against many solid tumors

New study reveals illicit HGH use among young American male weightlifters

Biomarin commences BMN 701 Phase 1/2 trial for treatment of Pompe disease

Scientists produce tiny molecular 'binder' that may help develop more efficient drugs

Postmenopausal women receiving estrogen plus progestin at increased risk of breast cancer

Platelet-rich plasma shows a promising biologic treatment for myocardial infarction: Study

pH Advantage adds Pyranase to facial skin care line

12-HETE enzyme inhibition can prevent ischemic retinopathy: Study

FibroGen initiates FG-3019 open-label phase 2 study in idiopathic pulmonary fibrosis

Pfizer initiates rolling submission of crizotinib NDA for ALK-positive advanced NSCLC

Daiichi Sankyo and ArQule initiate enrollment in ARQ 197 Phase 3 trial in NSCLC

Basal-like breast cancer is equally aggressive disease in African American women and white women: Study

Nutriceuticals may restore age-related vision loss

Scientists discover new anti-cancer mechanism

HRG protein inhibits tumor growth and metastasis: Study

New research: NFKBIA gene loss induces glioblastoma development

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

Latest News